Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
- Breast Cancer
- Breast Cancer Risk
- Transform Growth Factor Beta
- Mammary Gland Development
- Transform Growth Factor Beta Receptor
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Hanahan, D. and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57–70, 2000.
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. Creation of human tumour cells with defined genetic elements. Nature, 400: 464–468, 1999.
Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J., and Massague, J. Transforming growth factor {beta} signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. PNAS, 100: 8430, 2003.
Massague, J. Tgf-beta signal transduction [Review]. Annual Review of Biochemistry, 67: 753–791, 1998.
Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res., 47: 707–712, 1987.
Dickson, R. B., Kasid, A., Huff, K. K., Bates, S. E., Knabbe, C., Bronzert, D., Gelmann, E. P., and Lippman, M. E. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc.Natl.Acad.Sci.U.S.A, 84: 837–841, 1987.
Lyons, R. M., Gentry, L. E., Purchio, A. F., and Moses, H. L. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J.Cell Biol., 110: 1361–1367, 1990.
Sato, Y. and Rifkin, D. B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J.Cell Biol., 109: 309–315, 1989.
Crawford, S. E., Stellmach, V., Murphyullrich, J. E., Ribeiro, S. F., Lawler, J., Hynes, R. O., Boivin, G. P., and Bouck, N. Thrombospondin-1 is a major activator of tgf-beta-1 in vivo. Cell, 93: 1159–1170, 1998.
Yu, Q. and Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev., 14: 163–176, 2000.
Stamenkovic, I. Matrix metalloproteinases in tumor invasion and metastasis. Semin.Cancer Biol., 10: 415–433, 2000.
Stetler-Stevenson, W. G. and Yu, A. E. Proteases in invasion: matrix metalloproteinases. Semin.Cancer Biol., 11: 143–152, 2001.
Aghdasi, B., Ye, K., Resnick, A., Huang, A., Ha, H. C., Guo, X., Dawson, T. M., Dawson, V. L., and Snyder, S. H. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc.Natl.Acad.Sci.U.S.A, 98: 2425–2430, 2001.
Wang, T., Li, B. Y., Danielson, P. D., Shah, P. C., Rockwell, S., Lechleider, R. J., Martin, J., Manganaro, T., and Donahoe, P. K. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell, 86: 435–444, 1996.
Yao, D., Dore, J. J., Jr., and Leof, E. B. FKBP12 is a negative regulator of transforming growth factor-beta receptor internalization. J.Biol.Chem., 275: 13149–13154, 2000.
Datta, P. K., Chytil, A., Gorska, A. E., and Moses, H. L. Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling. J.Biol.Chem., 273: 34671–34674, 1998.
Griswold-Prenner, I., Kamibayashi, C., Maruoka, E. M., Mumby, M. C., and Derynck, R. Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. Mol.Cell Biol., 18: 6595–6604, 1998.
Massague, J. How cells read TGF-beta signals. Nat.Rev.Mol.Cell Biol., 1: 169–178, 2000.
Itoh, S., Itoh, F., Goumans, M. J., and ten Dijke, P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur.J.Biochem., 267: 6954–6967, 2000.
Derynck, R. and Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425: 577–584, 2003.
Dunfield, L. D., Dwyer, E. J., and Nachtigal, M. W. TGF beta-induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology, 143: 1174–1181, 2002.
Ulloa, L., Doody, J., and Massague, J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature, 397: 710–713, 1999.
Bitzer, M., von Gersdorff, G., Liang, D., Dominguez-Rosales, A., Beg, A. A., Rojkind, M., and Bottinger, E. P. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev., 14: 187–197, 2000.
Kretzschmar, M., Doody, J., Timokhina, I., and Massague, J. A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev., 13: 804–816, 1999.
Yu, L., Hebert, M. C., and Zhang, Y. E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J, 21: 3749–3759, 2002.
Edlund, S., Bu, S., Schuster, N., Aspenstrom, P., Heuchel, R., Heldin, N. E., ten Dijke, P., Heldin, C. H., and Landstrom, M. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol.Biol.Cell, 14: 529–544, 2003.
Hannon, G. J. and Beach, D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature, 371: 257–261, 1994.
Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev., 9: 1831–1845, 1995.
Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc.Natl.Acad.Sci.U.S.A, 92: 5545–5549, 1995.
Rotello, R. J., Lieberman, R. C., Purchio, A. F., and Gerschenson, L. E. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor beta 1 in cultured uterine epithelial cells. Proc.Natl.Acad.Sci.U.S.A, 88: 3412–3415, 1991.
Oberhammer, F. A., Pavelka, M., Sharma, S., Tiefenbacher, R., Purchio, A. F., Bursch, W., and Schulte-Hermann, R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc.Natl.Acad.Sci.U.S.A, 89: 5408–5412, 1992.
Chaouchi, N., Arvanitakis, L., Auffredou, M. T., Blanchard, D. A., Vazquez, A., and Sharma, S. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and lymphoma B cell lines. Oncog., 11: 1615–1622, 1995.
Landstrom, M., Heldin, N. E., Bu, S., Hermansson, A., Itoh, S., ten Dijke, P., and Heldin, C. H. Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells. Curr.Biol., 10: 535–538, 2000.
Larisch, S., Yi, Y., Lotan, R., Kerner, H., Eimerl, S., Tony, P. W., Gottfried, Y., Birkey, R. S., de Caestecker, M. P., Danielpour, D., Book-Melamed, N., Timberg, R., Duckett, C. S., Lechleider, R. J., Steller, H., Orly, J., Kim, S. J., and Roberts, A. B. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat.Cell Biol., 2: 915–921, 2000.
Patil, S., Wildey, G. M., Brown, T. L., Choy, L., Derynck, R., and Howe, P. H. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-beta-induced growth inhibition and apoptosis. J.Biol.Chem., 275: 38363–38370, 2000.
Perlman, R., Schiemann, W. P., Brooks, M. W., Lodish, H. F., and Weinberg, R. A. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat.Cell Biol., 3: 708–714, 2001.
Yanagisawa, K., Osada, H., Masuda, A., Kondo, M., Saito, T., Yatabe, Y., Takagi, K., Takahashi, T., and Takahashi, T. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncog., 17: 1743–1747, 1998.
Dai, J. L., Bansal, R. K., and Kern, S. E. G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation. Proc.Natl.Acad.Sci.U.S.A, 96: 1427–1432, 1999.
Silberstein, G. B. and Daniel, C. W. Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science, 237: 291–293, 1987.
Gomm, J. J., Smith, J., Ryall, G. K., Baillie, R., Turnbull, L., and Coombes, R. C. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res., 51: 4685–4692, 1991.
Lu, Y. J., Osin, P., Lakhani, S. R., Di Palma, S., Gusterson, B. A., and Shipley, J. M. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res., 58: 4721–4727, 1998.
Chakravarthy, D., Green, A. R., Green, V. L., Kerin, M. J., and Speirs, V. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. Int.J.Oncol., 15: 187–194, 1999.
Robinson, S. D., Silberstein, G. B., Roberts, A. B., Flanders, K. C., and Daniel, C. W. Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development, 113: 867–878, 1991.
Barcellos-Hoff, M. H., Derynck, R., Tsang, M. L., and Weatherbee, J. A. Transforming growth factor-beta activation in irradiated murine mammary gland. J.Clin.Invest, 93: 892–899, 1994.
Ehrhart, E. J., Segarini, P., Tsang, M. L., Carroll, A. G., and Barcellos-Hoff, M. H. Latent transforming growth factor betal activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. FASEB J., 11: 991–1002, 1997.
Robinson, S. D., Roberts, A. B., and Daniel, C. W. TGF beta suppresses casein synthesis in mouse mammary explants and may play a role in controlling milk levels during pregnancy. J.Cell Biol., 120: 245–251, 1993.
Bergstraesser, L., Sherer, S., Panos, R., and Weitzman, S. Stimulation and inhibition of human mammary epithelial cell duct morphogenesis in vitro. Proc.Assoc.Am.Physicians, 108: 140–154, 1996.
Soriano, J. V., Orci, L., and Montesano, R. TGF-beta1 induces morphogenesis of branching cords by cloned mammary epithelial cells at subpicomolar concentrations. Biochem.Biophys.Res.Commun., 220: 879–885, 1996.
Pierce, D. F., Jr., Gorska, A. E., Chytil, A., Meise, K. S., Page, D. L., Coffey, R. J., Jr., and Moses, H. L. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc.Natl.Acad.Sci.U.S.A, 92: 4254–4258, 1995.
Bottinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K., and Wakefield, L. M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res., 57: 5564–5570, 1997.
Fynan, T. M. and Reiss, M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev.Oncog., 4: 493–540, 1993.
Gobbi, H., Arteaga, C. L., Jensen, R. A., Simpson, J. F., Dupont, W. D., Olson, S. J., Schuyler, P. A., Plummer, W. D., Jr., and Page, D. L. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology, 36: 168–177, 2000.
Wakefield, L. M., Yang, Y. A., and Dukhanina, O. Transforming growth factor-beta and breast cancer: Lessons learned from genetically altered mouse models. Breast Cancer Res., 2: 100–106, 2000.
Gorsch, S. M., Memoli, V. A., Stukel, T. A., Gold, L. I., and Arrick, B. A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res., 52: 6949–6952, 1992.
Wakefield, L. M. and Roberts, A. B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr.Opin.Genet.Dev., 12: 22–29, 2002.
Akhurst, R. J. and Derynck, R. TGF-beta signaling in cancer—a double-edged sword. Trends Cell Biol., 11: S44–S51, 2001.
Sporn, M. B. and Roberts, A. B. TGF-beta: problems and prospects. Cell Regul., 1: 875–882, 1990.
Tang, B., Bottinger, E. P., Jakowlew, S. B., Bagnall, K. M., Mariano, J., Anver, M. R., Letterio, J. J., and Wakefield, L. M. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat.Med., 4: 802–807, 1998.
Koli, K. M. and Arteaga, C. L. Processing of the transforming growth factor beta type I and II receptors. Biosynthesis and ligand-induced regulation. J.Biol.Chem., 272: 6423–6427, 1997.
Chen, T., Carter, D., Garrigue-Antar, L., and Reiss, M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res., 58: 4805–4810, 1998.
Anbazhagan, R., Bornman, D. M., Johnston, J. C., Westra, W. H., and Gabrielson, E. The S387Y mutation of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. Cancer Res, 59: 3363–3364, 1999.
Schutte, M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., Sidransky, D., Casero, R. A., Jr., Meltzer, P. S., Hahn, S. A., and Kern, S. E. DPC4 gene in various tumor types. Cancer Res., 56: 2527–2530, 1996.
Verbeek, B. S., Adriaansen-Slot, S. S., Rijksen, G., and Vroom, T. M. Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J.Pathol., 183: 195–203, 1997.
Pasche, B., Luo, Y., Rao, P. H., Nimer, S. D., Dmitrovsky, E., Caron, P., Luzzatto, L., Offit, K., Cordon-Cardo, C., Renault, B., Satagopan, J. M., Murty, V. V., and Massague, J. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res., 58: 2727–2732, 1998.
Pasche, B., Kolachana, P., Nafa, K., Satagopan, J., Chen, Y. G., Lo, R. S., Brener, D., Yang, D., Kirstein, L., Oddoux, C., Ostrer, H., Vineis, P., Varesco, L., Jhanwar, S., Luzzatto, L., Massague, J., and Offit, K. T beta R-I(6A) is a candidate tumor susceptibility allele. Cancer Res, 59: 5678–5682, 1999.
Chen, T., de Vries, E. G., Hollema, H., Yegen, H. A., Vellucci, V. F., Strickler, H. D., Hildesheim, A., and Reiss, M. Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int.J Cancer, 82: 43–51, 1999.
Kaklamani, V. G., Hou, N., Bian, Y., Reich, J., Offit, K., Michel, L. S., Rubinstein, W. S., Rademaker, A., and Pasche, B. TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies. J Clin Oncol, 21: 3236–3243, 2003.
Pasche, B., Kaklamani, V. G., Hou, N., Young, T., Rademaker, A., Peterlongo, P., Ellis, N., Offit, K., Caldes, T., Reiss, M., and Zheng, T. TGFBR1*6A and Cancer: A Meta-Analysis of 12 Case-Control Studies. J Clin Oncol, 22: 756–758, 2004.
Dunning, A. M., Ellis, P. D., McBride, S., Kirschenlohr, H. L., Healey, C. S., Kemp, P. R., Luben, R. N., Chang-Claude, J., Mannermaa, A., Kataja, V., Pharoah, P. D. P., Easton, D. F., Ponder, B. A. J., and Metcalfe, J. C. A Transforming Growth Factor{beta} 1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer. Cancer Res, 63: 2610–2615, 2003.
Ziv, E., Cauley, J., Morin, P. A., Saiz, R., and Browner, W. S. Association between the T29→C polymorphism in the transforming growth factor betal gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA, 285: 2859–2863, 2001.
Hishida, A., Iwata, H., Hamajima, N., Matsuo, K., Mizutani, M., Iwase, T., Miura, S., Emi, N., Hirose, K., and Tajima, K. Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer, 10: 63–69, 2003.
Marchand, L. L., Haiman, C. A., van den Berg, D., Wilkens, L. R., Kolonel, L. N., and Henderson, B. E. T29C Polymorphism in the Transforming Growth Factor {beta} 1 Gene and Postmenopausal Breast Cancer Risk: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev, 13: 412–415, 2004.
Shu, X. O., Gao, Y. T., Cai, Q., Pierce, L., Cai, H., Ruan, Z. X., Yang, G., Jin, F., and Zheng, W. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res., 64: 836–839, 2004.
Sheen-Chen, S. M., Chen, H. S., Sheen, C. W., Eng, H. L., and Chen, W. J. Serum levels of transforming growth factor betal in patients with breast cancer. Arch.Surg., 136: 937–940, 2001.
Ivanovic, V., Todorovic-Rakovic, N., Demajo, M., Neskovic-Konstantinovic, Z., Subota, V., Ivanisevic-Milovanovic, O., and Nikolic-Vukosavljevic, D. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur.J.Cancer, 39: 454–461, 2003.
Lauritsen, K. J., List, H. J., Reiter, R., Wellstein, A., and Riegel, A. T. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene, 21: 7147–7155, 2002.
Brandt, S., Kopp, A., Grage, B., and Knabbe, C. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Anticancer Res., 23: 223–229, 2003.
Tong, G. M., Rajah, T. T., Zang, X. P., and Pento, J. T. The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells. Anticancer Res., 22: 103–106, 2002.
Wu, L., Wu, Y., Gathings, B., Wan, M., Li, X., Grizzle, W., Liu, Z., Lu, C., Mao, Z., and Cao, X. Smad4 as a transcription corepressor for estrogen receptor alpha. J.Biol.Chem., 278: 15192–15200, 2003.
Fumagalli, S., Doneda, L., Nomura, N., and Larizza, L. Expression of the c-ski proto-oncogene in human melanoma cell lines. Melanoma Res., 3: 23–27, 1993.
Luo, K., Stroschein, S. L., Wang, W., Chen, D., Martens, E., Zhou, S., and Zhou, Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev., 13: 2196–2206, 1999.
He, J., Tegen, S. B., Krawitz, A. R., Martin, G. S., and Luo, K. The Transforming Activity of Ski and SnoN Is Dependent on Their Ability to Repress the Activity of Smad Proteins. Journal of Biological Chemistry, 278: 30540–30547, 2003.
Zhang, F., Lundin, M., Ristimaki, A., Heikkila, P., Lundin, J., Isola, J., Joensuu, H., and Laiho, M. Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res., 63: 5005–5010, 2003.
Chen, T., Triplett, J., Dehner, B., Hurst, B., Colligan, B., Pemberton, J., Graff, J. R., and Carter, J. H. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res, 61: 4679–4682, 2001.
Hahm, K. B., Cho, K., Lee, C., Im, Y. H., Chang, J., Choi, S. G., Sorensen, P. H., Thiele, C. J., and Kim, S. J. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat.Genet., 23: 222–227, 1999.
Benson, J. R. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol., 5: 229–239, 2004.
Laiho, M., Decaprio, J. A., Ludlow, J. W., Livingston, D. M., and Massague, J. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell, 62: 175–185, 1990.
Howe, P. H., Draetta, G., and Leof, E. B. Transforming growth factor beta 1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest. Mol.Cell Biol., 11: 1185–1194, 1991.
Alexandrow, M. G. and Moses, H. L. Transforming growth factor beta and cell cycle regulation. Cancer Res., 55: 1452–1457, 1995.
Coffey, R. J., Jr., Bascom, C. C., Sipes, N. J., Graves-Deal, R., Weissman, B. E., and Moses, H. L. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol.Cell Biol., 8: 3088–3093, 1988.
Pietenpol, J. A., Stein, R. W., Moran, E., Yaciuk, P., Schlegel, R., Lyons, R. M., Pittelkow, M. R., Munger, K., Howley, P. M., and Moses, H. L. TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 61: 777–785, 1990.
Alexandrow, M. G., Kawabata, M., Aakre, M., and Moses, H. L. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc.Natl.Acad.Sci.U.S.A, 92: 3239–3243, 1995.
Slingerland, J. M., Hengst, L., Pan, C. H., Alexander, D., Stampfer, M. R., and Reed, S. I. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol.Cell Biol., 14: 3683–3694, 1994.
Geng, Y. and Weinberg, R. A. Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc.Natl.Acad.Sci.U.S.A, 90: 10315–10319, 1993.
Koff, A., Ohtsuki, M., Polyak, K., Roberts, J. M., and Massague, J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science, 260: 536–539, 1993.
Lammie, G. A., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michalides, R., Dickson, C., Arnold, A., and Peters, G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene, 6: 439–444, 1991.
Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127–2133, 1993.
An, H. X., Beckmann, M. W., Reifenberger, G., Bender, H. G., and Niederacher, D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am.J.Pathol., 154: 113–118, 1999.
Jansen-Durr, P., Meichle, A., Steiner, P., Pagano, M., Finke, K., Botz, J., Wessbecher, J., Draetta, G., and Eilers, M. Differential modulation of cyclin gene expression by MYC. Proc.Natl.Acad.Sci.U.S.A, 90: 3685–3689, 1993.
Shibuya, H., Yoneyama, M., Ninomiya-Tsuji, J., Matsumoto, K., and Taniguchi, T. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: demonstration of a novel role for c-myc. Cell, 70: 57–67, 1992.
Aktas, H., Cai, H., and Cooper, G. M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol.Cell Biol., 17: 3850–3857, 1997.
Cheng, M., Sexl, V., Sherr, C. J., and Roussel, M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc.Natl.Acad.Sci.U.S.A, 95: 1091–1096, 1998.
Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev., 12: 3499–3511, 1998.
Derynck, R., Akhurst, R. J., and Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat.Genet., 29: 117–129, 2001.
Oft, M., Akhurst, R. J., and Balmain, A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat.Cell Biol., 4: 487–494, 2002.
Portella, G., Cumming, S. A., Liddell, J., Cui, W., Ireland, H., Akhurst, R. J., and Balmain, A. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ., 9: 393–404, 1998.
Cui, W., Fowlis, D. J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., and Akhurst, R. J. TGFbetal inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell, 86: 531–542, 1996.
Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massague, J., Mundy, G. R., and Guise, T. A. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigation, 103: 197–206, 1999.
Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int.J.Cancer, 72: 1–22, 1997.
Ueki, N., Nakazato, M., Ohkawa, T., Ikeda, T., Amuro, Y., Hada, T., and Higashino, K. Excessive production of transforming growth-factor beta 1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochimica et Biophysica Acta, 1137: 189–196, 1992.
Schwarte-Waldhoff, I., Volpert, O. V., Bouck, N. P., Sipos, B., Hahn, S. A., Klein-Scory, S., Luttges, J., Kloppel, G., Graeven, U., Eilert-Micus, C., Hintelmann, A., and Schmiegel, W. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc.Natl.Acad.Sci.U.S.A, 97: 9624–9629, 2000.
de Jong, J. S., van Diest, P. J., van, d., V, and Baak, J. P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J.Pathol., 184: 53–57, 1998.
Ito, N., Kawata, S., Tamura, S., Shirai, Y., Kiso, S., Tsushima, H., and Matsuzawa, Y. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett., 89: 45–48, 1995.
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V., Kehrl, J. H., and. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc.Natl.Acad.Sci.U.S.A, 83: 4167–4171, 1986.
Sunderkotter, C., Goebeler, M., Schulze-Osthoff, K., Bhardwaj, R., and Sorg, C. Macrophage-derived angiogenesis factors. Pharmacol.Ther., 51: 195–216, 1991.
Yang, E. Y. and Moses, H. L. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J.Cell Biol., 111: 731–741, 1990.
Ashcroft, G. S. Bidirectional regulation of macrophage function by TGF-beta. Microbes.Infect., 1: 1275–1282, 1999.
Edwards, D. R., Murphy, G., Reynolds, J. J., Whitham, S. E., Docherty, A. J., Angel, P., and Heath, J. K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J., 6: 1899–1904, 1987.
Kordula, T., Guttgemann, I., Rose-John, S., Roeb, E., Osthues, A., Tschesche, H., Koj, A., Heinrich, P. C., and Graeve, L. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). Up-regulation by interleukin-6 and transforming growth factor beta 1. FEBS Lett., 313: 143–147, 1992.
Shimizu, S., Nishikawa, Y., Kuroda, K., Takagi, S., Kozaki, K., Hyuga, S., Saga, S., and Matsuyama, M. Involvement of transforming growth factor betal in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res., 56: 3366–3370, 1996.
Sehgal, I. and Thompson, T. C. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and-2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol.Biol.Cell, 10: 407–416, 1999.
Duivenvoorden, W. C., Hirte, H. W., and Singh, G. Transforming growth factor betal acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin.Exp.Metastasis, 17: 27–34, 1999.
Hagedorn, H. G., Bachmeier, B. E., and Nerlich, A. G. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). Int.J.Oncol., 18: 669–681, 2001.
Kalembeyi, I., Inada, H., Nishiura, R., Imanaka-Yoshida, K., Sakakura, T., and Yoshida, T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor betal. Int.J.Cancer, 105: 53–60, 2003.
Letamendia, A., Lastres, P., Botella, L. M., Raab, U., Langa, C., Velasco, B., Attisano, L., and Bemabeu, C. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem, 273: 33011–9, 1998.
Barbara, N. P., Wrana, J. L., and Letarte, M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem, 274: 584–94, 1999.
Li, C., Hampson, I. N., Hampson, L., Kumar, P., Bernabeu, C., and Kumar, S. CD105 antagonizes the inhibitory signaling of transforming growth factor betal on human vascular endothelial cells. FASEB J, 14: 55–64, 2000.
Lastres, P., Letamendia, A., Zhang, H., Rius, C., Almendro, N., Raab, U., Lopez, L. A., Langa, C., Fabra, A., Letarte, M., and Bemabeu, C. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol, 133: 1109–21, 1996.
Seon, B. K., Matsuno, F., Haruta, Y., Kondo, M., and Barcos, M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res, 3: 1031–44, 1997.
Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M., and Seon, B. K. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res, 5: 371–82, 1999.
Tabata, M., Kondo, M., Haruta, Y., and Seon, B. K. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int J Cancer, 82: 737–42, 1999.
Dalal, B. I., Keown, P. A., and Greenberg, A. H. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am.J.Pathol., 143: 381–389, 1993.
Kakonen, S. M., Selander, K. S., Chirgwin, J. M., Yin, J. J., Bums, S., Rankin, W. A., Grubbs, B. G., Dallas, M., Cui, Y., and Guise, T. A. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J.Biol.Chem., 277: 24571–24578, 2002.
Reinholz, M. M., Iturria, S. J., Ingle, J. N., and Roche, P. C. Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res.Treat., 74: 255–269, 2002.
Oft, M., Heider, K. H., and Beug, H. Tgf-beta signaling is necessary for carcinoma cell invasiveness and metastasis. Current Biology, 8: 1243–1252, 1998.
Oft, M., Peli, J., Rudaz, C., Schwarz, H., Beug, H., and Reichmann, E. Tgf-beta-1 and ha-ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev, 10: 2462–2477, 1996.
Miettinen, P. J., Ebner, R., Lopez, A. R., and Derynck, R. Tgf-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type i receptors. Journal of Cell Biology, 127: Pt 2):2021–36, 1994.
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., and Moses, H. L. TGF-{beta} Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia. Science, 303: 848–851, 2004.
Fortunel, N., Hatzfeld, J., Kisselev, S., Monier, M. N., Ducos, K., Cardoso, A., Batard, P., and Hatzfeld, A. Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-beta type II receptor in a short-term in vitro assay. Stem Cells, 18: 102–111, 2000.
Fortunel, N. O., Hatzfeld, A., and Hatzfeld, J. A. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood, 96: 2022–2036, 2000.
Keller, J. R., McNiece, I. K., Sill, K. T., Ellingsworth, L. R., Quesenberry, P. J., Sing, G. K., and Ruscetti, F. W. Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation. Blood, 75: 596–602, 1990.
Soma, T., Yu, J. M., and Dunbar, C. E. Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. Blood, 87: 4561–4567, 1996.
Keller, J. R., Jacobsen, S. E., Sill, K. T., Ellingsworth, L. R., and Ruscetti, F. W. Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc.Natl.Acad.Sci.U.S.A, 88: 7190–7194, 1991.
Jacobsen, S. E., Ruscetti, F. W., Dubois, C. M., Lee, J., Boone, T. C., and Keller, J. R. Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood, 77: 1706–1716, 1991.
Hatzfeld, J., Li, M. L., Brown, E. L., Sookdeo, H., Levesque, J. P., O'Toole, T., Gurney, C., Clark, S. C., and Hatzfeld, A. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. J.Exp.Med., 174: 925–929, 1991.
Batard, P., Monier, M. N., Fortunel, N., Ducos, K., Sansilvestri-Morel, P., Phan, T., Hatzfeld, A., and Hatzfeld, J. A. TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. J.Cell Sci., 113 (Pt 3): 383–390, 2000.
Marone, M., Scambia, G., Bonanno, G., Rutella, S., de Ritis, D., Guidi, F., Leone, G., and Pierelli, L. Transforming growth factor-beta1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia, 16: 94–105, 2002.
Pierelli, L., Marone, M., Bonanno, G., Mozzetti, S., Rutella, S., Morosetti, R., Rumi, C., Mancuso, S., Leone, G., and Scambia, G. Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. Blood, 95: 3001–3009, 2000.
Knaus, P. I., Lindemann, D., DeCoteau, J. F., Perlman, R., Yankelev, H., Hille, M., Kadin, M. E., and Lodish, H. F. A dominant inhibitory mutant of the type ii transforming growth factor beta receptor in the malignant progression of a cutaneous t-cell lymphoma. Molecular & Cellular Biology, 16: 3480–3489, 1996.
Schiemann, W. P., Pfeifer, W. M., Levi, E., Kadin, M. E., and Lodish, H. F. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood, 94: 2854–2861, 1999.
Bouchard, C., Fridman, W. H., and Sautes, C. Mechanism of inhibition of lipopolysaccharide-stimulated mouse B-cell responses by transforming growth factor-beta 1. Immunol.Lett., 40: 105–110, 1994.
Kehrl, J. H., Thevenin, C., Rieckmann, P., and Fauci, A. S. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J.Immunol., 146: 4016–4023, 1991.
Kiessling, R., Klein, E., and Wigzell, H. "e;Natural"e; killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur.J.Immunol., 5: 112–117, 1975.
Kiessling, R., Klein, E., Pross, H., and Wigzell, H. "e;Natural"e; killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur.J.Immunol., 5: 117–121, 1975.
Perussia, B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr.Opin.Immunol., 3: 49–55, 1991.
Karre, K., Ljunggren, H. G., Piontek, G., and Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature, 319: 675–678, 1986.
Bellone, G., Aste-Amezaga, M., Trinchieri, G., and Rodeck, U. Regulation of NK cell functions by TGF-beta 1. J.Immunol., 155: 1066–1073, 1995.
Pierson, B. A., Gupta, K., Hu, W. S., and Miller, J. S. Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors. Blood, 87: 180–189, 1996.
Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., and Fauci, A. S. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J.Immunol., 136: 3916–3920, 1986.
Kripke, M. L. Antigenicity of murine skin tumors induced by ultraviolet light. J.Natl.Cancer Inst., 53: 1333–1336, 1974.
Urban, J. L., Burton, R. C., Holland, J. M., Kripke, M. L., and Schreiber, H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J.Exp.Med., 155: 557–573, 1982.
Seliger, B., Maeurer, M. J., and Ferrone, S. TAP off—tumors on. Immunol.Today, 18: 292–299, 1997.
Doherty, P. C., Knowles, B. B., and Wettstein, P. J. Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv.Cancer Res., 42: 1–65, 1984.
Ferrone, S. and Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol.Today, 16: 487–494, 1995.
Hellstrom, K. E., Hellstrom, I., and Chen, L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol.Rev., 145: 123–145, 1995.
Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G., and Nadler, L. M. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc.Natl.Acad.Sci.U.S.A, 90: 6586–6590, 1993.
Wojtowicz-Praga, S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J.Immunother., 20: 165–177, 1997.
Letterio, J. J. and Roberts, A. B. Regulation of immune responses by TGF-beta. Annu.Rev.Immunol., 16: 137–161, 1998.
Czarniecki, C. W., Chiu, H. H., Wong, G. H., McCabe, S. M., and Palladino, M. A. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J.Immunol., 140: 4217–4223, 1988.
Geiser, A. G., Letterio, J. J., Kulkarni, A. B., Karlsson, S., Roberts, A. B., and Spom, M. B. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc.Natl.Acad.Sci.U.S.A, 90: 9944–9948, 1993.
Letterio, J. J., Geiser, A. G., Kulkarni, A. B., Dang, H., Kong, L. P., Nakabayashi, T., Mackall, C. L., Gress, R. E., and Roberts, A. B. Autoimmunity associated with tgf-beta-I-deficiency in mice is dependent on mhc class ii antigen expression. Journal of Clinical Investigation, 98: 2109–2119, 1996.
Arteaga, C. L., Koli, K. M., Dugger, T. C., and Clarke, R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J.Natl.Cancer Inst., 91: 46–53, 1999.
Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., and Dickson, R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48: 417–428, 1987.
Screpanti, I., Santoni, A., Gulino, A., Herberman, R. B., and Frati, L. Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes. Cell Immunol., 106: 191–202, 1987.
Mandeville, R., Ghali, S. S., and Chausseau, J. P. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur.J.Cancer Clin.Oncol., 20: 983–985, 1984.
Berry, J., Green, B. J., and Matheson, D. S. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur.J.Cancer Clin.Oncol., 23: 517–520, 1987.
Baral, E., Nagy, E., and Berczi, I. Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer, 75: 591–599, 1995.
Gottardis, M. M., Wagner, R. J., Borden, E. C., and Jordan, V. C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res., 49: 4765–4769, 1989.
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., and Sobol, R. E. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc.Natl.Acad.Sci.U.S.A, 93: 2909–2914, 1996.
Won, J., Kim, H., Park, E. J., Hong, Y., Kim, S. J., and Yun, Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res, 59: 1273–7, 1999.
Shah, A. H. and Lee, C. TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. Prostate, 45: 167–172, 2000.
Shah, A. H., Tabayoyong, W. B., Kundu, S. D., Kim, S. J., Van Parijs, L., Liu, V. C., Kwon, E., Greenberg, N. M., and Lee, C. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res, 62: 7135–8, 2002.
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., Koteliansky, V., and Arteaga, C. L. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest, 109: 1551–1559, 2002.
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., and Karlsson, S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc.Natl.Acad.Sci.U.S.A, 90: 770–774, 1993.
Dang, H., Geiser, A. G., Letterio, J. J., Nakabayashi, T., Kong, L., Fernandes, G., and Talal, N. SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J.Immunol., 155: 3205–3212, 1995.
Yang, Y. A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z. Y., Green, J., Anver, M. R., Merlino, G., and Wakefield, L. M. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J.Clin.Invest, 109: 1607–1615, 2002.
Callahan, J. F., Burgess, J. L., Fornwald, J. A., Gaster, L. M., Harling, J. D., Harrington, F. P., Heer, J., Kwon, C., Lehr, R., Mathur, A., Olson, B. A., Weinstock, J., and Laping, N. J. Identification of novel inhibitors of the transforming growth factor betal (TGF-beta1) type 1 receptor (ALK5). J.Med.Chem., 45: 999–1001, 2002.
Inman, G. J., Nicolas, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., and Hill, C. S. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol.Pharmacol., 62: 65–74, 2002.
Eyers, P. A., Craxton, M., Morrice, N., Cohen, P., and Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem.Biol., 5: 321–328, 1998.
Laping, N. J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J. F., and Olson, B. A. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol.Pharmacol., 62: 58–64, 2002.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Kaklamani, V., Pasche, B. (2005). Transforming Growth Factor Beta and Breast Cancer. In: Platanias, L.C. (eds) Cytokines and Cancer. Cancer Treatment and Research, vol 126. Springer, Boston, MA. https://doi.org/10.1007/0-387-24361-5_6
Download citation
DOI: https://doi.org/10.1007/0-387-24361-5_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24360-3
Online ISBN: 978-0-387-24361-0
eBook Packages: MedicineMedicine (R0)